Alzheimer's Disease Drug Development Program (U01)
The summary for the Alzheimer's Disease Drug Development Program (U01) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Alzheimer's Disease Drug Development Program (U01): -Purpose. The objective of this solicitation is to stimulate research in the pre-clinical development and testing of novel therapeutic compounds aimed at slowing, halting, or reversing the progressive decline in cognitive function and modifying the behavioral symptoms in Alzheimer's disease (AD); or delaying the onset of or preventing AD, mild cognitive impairment (MCI), or age-related cognitive decline. This initiative is intended to stimulate activities focused on providing sufficient data to submit an Investigational New Drug (IND) application to the Food and Drug Administration to begin human clinical testing of potential new therapies. For this program neither mechanistic/basic studies nor clinical trials will be supported; only applications to develop a therapy will be accepted. -Mechanism of Support. This FOA uses the NIH U01 mechanism -Funds Available and Anticipated Number of Awards. NIA has set aside $2.5 M in total costs in FY2009 for applications submitted in response to this program announcement. However, because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received.
Federal Grant Title: | Alzheimer's Disease Drug Development Program (U01) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-08-266 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.866 |
CFDA Descriptions: | Aging Research |
Current Application Deadline: | No deadline provided |
Original Application Deadline: | Jan 07, 2012 |
Posted Date: | Sep 18, 2008 |
Creation Date: | Dec 03, 2008 |
Archive Date: | Dec 04, 2008 |
Total Program Funding: | $2,500,000 |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations).
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Nathan Shock Centers Coordinating Center (U24 Clinical Trial Not Allowed)
- • Nathan Shock Centers of Excellence in Basic Biology of Aging (P30 Clinical Trial Not Allow...
- • Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (...
- • Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumul...
- • Research Training in Aging for Medical Students (T35)
- • Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...
- • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...
- • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
- More Grants from the National Institutes of Health
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...